




PHARMACEUTICAL 2018

Nabriva Therapeutics plc
Rank 151 of 342





PHARMACEUTICAL 2018

Nabriva Therapeutics plc Rank 151 of 342

The relative strengths and weaknesses of Nabriva Therapeutics plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nabriva Therapeutics plc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 94% points. The greatest weakness of Nabriva Therapeutics plc is the variable Net Income, reducing the Economic Capital Ratio by 56% points.

The company's Economic Capital Ratio, given in the ranking table, is 122%, being 77% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	93,839
Cost of Goods Sold	0
Intangible Assets	172
Liabilities, Current	13,260
Liabilities, Non-Current	435
Other Assets	425
Other Compr. Net Income	17
Other Expenses	1,398
Other Liabilities	0
Other Net Income	6,129
Other Revenues	0
Property and Equipment	1,327
Research and Development	49,615
Selling, General and Administrative Expense	29,472

Output Variable	Value in 1000 USD
Assets	95,763
Liabilities	13,695
Expenses	80,485
Revenues	0
Stockholders Equity	82,068
Net Income	-74,356
Comprehensive Net Income	-74,348
Economic Capital Ratio	122%